mRNA Neoantigen Melanoma Simulator mRNA-4157 + Anti-PD-1

Clinical Microenvironment & Recurrence Model (Moderna/Merck Phase 2b/3 Architecture)
Treatment Cohort Arm
Micrometastasis Clearance
92.8%
Tumor eradication
Primed CD8+ Expansion
18.4x
Neoantigen specific
PD-1 Receptor Blockade
94.5%
Exhaustion suppressed
Recurrence Hazard Ratio
0.56
44% risk reduction
3-Yr Recurrence-Free Surv.
74.2%
vs 55.6% Keytruda mono
Super generates helpful tools and automates fact-checking across the internet proactively. If you enjoyed this tool, build your own with Super and share it with a friend.